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Integrins are adhesion receptors that connect cells to ligands in the extracellular matrix to other cells. Integrins are obligatory type I αβ-heterodimers that undergo large conformational changes in their extracellular domains in response to signalling events inside cells. This process, often referred to as inside-out signalling, is initiated by adaptor molecules that affect the position of the cytoplasmic tails of α-and β-subunits relative to each other and to the plasma membrane. For many, if not all, integrins, such conformational changes (activation) are required to actuate their adhesive function. Current dogma holds that the ligand-binding domain in resting integrins is not readily accessible to adhesive ligands.
The best-known positive regulators of integrin activation are the adaptor molecules: talin 1 (REF. 1 ) and the kindlins (kindlin 1, kindlin 2 and kindlin 3) 2 . In addition to their role in adhesion, integrins are also involved in signal transduction. Upon activation, integrins initiate ligand-dependent intracellular signalling, a process that is called outside-in signalling because it is initiated in late-stage clinical trials and to review ongoing efforts to develop new integrintargeted drugs. We focus on the mechanisms of action of such drugs and on what we have learned from their successes and failures, including expected and unexpected side effects. Previous reviews on this subject have focused on other aspects, including details of integrin structure and allosteric inhibitors 7 , leukocyte integrins 8 , integrins as possible targets in airway hyperresponsiveness 9 and integrin-targeting candidate molecules in early-stage trials 10 . Not all efforts in the integrin-targeting space have been successful; 10 years ago, high hopes were placed on allosteric inhibitors 7 , and large programmes to develop such drugs were undertaken by many major pharmaceutical companies.
Integrin biology and drug development
An important lesson from past integrin drug-development efforts is that successes are dependent on a combination of unmet clinical need and a deep understanding of basic mechanisms of cell adhesion. All integrin antagonists currently on the market or in late-stage clinical trials target the ligand-binding sites of integrins that are expressed on blood cells: leukocytes or platelets. Leukocyte and platelet integrins undergo conformational changes and 'activation' . The affinities of both leukocyte and platelet integrins are highly responsive to inside-out signalling. For example, leukocyte integrins can change their affinity by about 10,000-fold 11 . Nine of the 24 human integrins contain an 'inserted' domain (I-domain) that has homology to the von Willebrand factor A domain and is found in the extracellular portion of the α-subunit 12 (FIG. 1 ). All integrins with an I-domain bind to extracellular matrix ligands or counter-receptors on other cells through this domain. These integrins then undergo a conformational change, which provides an internal ligand for the β-subunit I-like domain. By contrast, all integrins without an I-domain bind to the ligand directly using a binding pocket that is formed by the most amino-terminal subunits of both the α-and β-polypeptide chains.
The conformational change that occurs during integrin activation involves extension of the α-and β-'legs' , rearrangement of the by the binding of extracellular ligands to the integrins. Outside-in signalling involves, in part, ligand-dependent integrin clustering, which brings the signalling domains of integrin-proximal proteins close enough together to initiate intracellular signals. Well-known intracellular events that are dependent on integrin outside-in signalling include activation of spleen tyrosine kinase (SYK) 3, 4 and SRC family protein tyrosine kinases in platelets 5 and leukocytes 3 , and activation of NADPH oxidase in leukocytes 6 . Because of their central roles in almost all phases of human biology as well as in the pathobiology of many diseases, integrins have long been a focus of the biotechnology and pharmaceutical industries as potential therapeutic targets. The first integrintargeted drug, abciximab, was introduced in 1994. Currently, ClinicalTrials.gov lists 80 clinical trials of integrin-based therapeutic drugs, imaging agents or biomarkers.
The purpose of this Opinion is to provide a biological context for integrins as drug targets, to highlight integrin antagonists that have shown benefit in patients or promise Abstract | Integrins are activatable molecules that are involved in adhesion and signalling. Of the 24 known human integrins, 3 are currently targeted thera peutically by monoclonal antibodies, peptides or small molecules: drugs targeting the platelet αIIbβ3 integrin are used to prevent thrombotic complications after percutaneous coronary interventions, and compounds targeting the lymphocyte α4β1 and α4β7 integrins have indications in multiple sclerosis and inflammatory bowel disease. New antibodies and small molecules targeting β7 integrins (α4β7 and αEβ7 integrins) and their ligands are in clinical development for the treatment of inflammatory bowel diseases. Integrin-based therapeutics have shown clinically significant benefits in many patients, leading to continued medical interest in the further development of novel integrin inhibitors. Of note, almost all integrin antagonists in use or in late-stage clinical trials target either the ligand-binding site or the ligand itself.
α-β interface within the ligand-binding domain and separation of the α-and β-'feet' (transmembrane domains) (FIG. 2) . The αL and β2 cytoplasmic tails of αLβ2 integrin (also known as lymphocyte functionassociated antigen 1 (LFA1)) have been shown to move apart when this integrin is activated 13 . This is thought to be a general process associated with integrin activation 14 , and several detailed models of integrin activation have been proposed 15, 16 . Most of the integrins without αI-domains, and none of the integrins with αI-domains, bind to the short peptide sequence Arg-Gly-Asp (RGD), which was first discovered by Pierschbacher and Ruoslahti 17 (FIG. 1) . Some of the drugs targeting platelet αIIbβ3 integrin are based on this RGD sequence. Another short amino acid sequence, Ile-Leu-Asp-Val, found in the type III connecting segment 1 (CS1) of fibronectin, was identified as a recognition sequence for α4β1 integrin 18 . The other integrins do not bind consensus peptide sequences; the recognition sites in their ligands may be nonlinear. A few integrins, such as αMβ2 integrin (also known as macrophage 1 (MAC1) and complement receptor 3 (CR3)), have also been reported to bind to non-protein ligands, such as glycans and glycolipids, but this seems to be the exception rather than the rule. All integrins that have been targeted for therapeutic purposes thus far normally bind binding) 11 (FIG. 2) . This model would predict three conformations: bent with a low-affinity headpiece, extended with a low-affinity headpiece, and extended with a high-affinity headpiece. Indeed, these conformations have been shown to exist on primary cells, and the extended conformation with low affinity can be stabilized by certain allosteric antagonists 21 . This conformation seems to support neutrophil rolling but not firm adhesion [22] [23] [24] . Although a large number of allosteric antagonists have been made that effectively inhibit either extension or the high-affinity conformation 7, 19, 25 , these have not been successful as systemic therapeutics. We speculate that either the specificity of these molecules was insufficient -each compound blocked multiple integrins -or unexpected systemic toxicity may have occurred. Alternatively, or in addition, the proposed conformational changes during activation, which have mainly been determined for αVβ3, αIIbβ3 and the β2-containing integrins, may not occur in α4β1 and α4β7 integrins, and so the allosteric inhibitors would not work for some therapeutically relevant integrins. A few allosteric inhibitors for α4β1 have been described in preclinical studies 26, 27 , but there is no evidence that any have been developed further or entered clinical trials.
The clinically successful integrin-directed drugs target αIIbβ3 (TABLE 1) , α4-containing
and α4β7 integrins (TABLE 2) . Therefore, the remainder of this Opinion is organized according to these targets, with a focus on new drugs.
Platelet integrins αIIbβ3 integrin. Inherited deficiency or dysfunction of αIIbβ3 integrin causes a rare but serious bleeding disorder, Glanzmann thrombasthenia, owing to the inability of activated platelets to aggregate in a liganddependent manner 28 . Platelets also express four other integrins, including α2β1 integrin, which binds to collagen, but the amount of platelet aggregation and granule secretion that occurs in response to collagen-dependent α2β1 integrin activation is minor compared to that downstream of the non-integrin collagen receptor platelet glycoprotein VI (GPVI) 29 . αIIbβ3 integrin has some affinity for immobilized fibrinogen even without deliberate platelet activation. When platelets are fully activated, αIIbβ3 integrin can bind to soluble fibrinogen, von Willebrand factor, fibronectin and vitronectin 28, 30 in a manner that depends on the presence of one or more of the RGD-containing sequences in the ligands or, in the case of fibrinogen, on to protein ligands, and the antibody, peptide or small-molecule antagonists that have made it to market all target the ligand-binding site. As integrins undergo large conformational changes during activation, allosteric inhibitors of the activation process have been proposed as drug targets 7 . Small molecules that act as allosteric inhibitors have been developed by pharmaceutical companies 19 , but none of them has made it to the market. Allosteric inhibitors probably have limited specificity and affect multiple integrins.
Integrins Integrins are heterodimers comprised of one α and one β subunit, as indicated by the black ovals. Integrins targeted for therapy are circled in red; the dotted red circle indicates past therapeutic use (for αLβ2 integrin) or unknown effects (antibodies to β7-containing integrins also target αEβ7 integrin, but α4β7 integrin is believed to be the relevant target). Integrins that bind to Arg-Gly-Asp (RGD) are circled in blue, I-domain-containing integrin-α subunits are grey.
the carboxy-terminus of the γ-chain 31, 32 . The dimeric fibrinogen molecule mediates platelet aggregation by serving as a bridge between αIIbβ3 integrins on adjacent platelets.
Inside-out activation of αIIbβ3 integrin has been very well studied 14 . The binding of talin 1 to a membrane-proximal region and an Asn-Pro-X-Tyr (NPXY) motif in the β3 cytoplasmic domain is key to this signalling cascade 1 . Identification of the gene responsible for a rare inherited bleeding disorder in which αIIbβ3 integrin cannot be activated has led to the recognition that kindlin 3 is also required for αIIbβ3 activation 33, 34 . The precise mechanisms by which kindlin 3 influences integrin activation are incompletely understood, but seem to involve, at least in part, the interaction of kindlin 3 with the C-terminal region of the β3 integrin cytoplasmic domain and clustering of αIIbβ3 integrin heterodimers into oligomers 35 . All reported patients with a null mutation in FERMT3, which encodes kindlin3, also exhibit defective activation of their leukocyte integrins 34 , which results in recurrent infections. The syndrome is therefore known as leukocyte adhesion deficiency type III (LAD3, also known as LAD type I variant).
After blood cell development, αIIbβ3 integrin is expressed exclusively in megakaryocytes and platelets. This restricted expression and the obligatory requirement for ligand binding to αIIbβ3 integrin in platelet aggregation during haemostasis and thrombosis led investigators to consider this integrin as a potential therapeutic target for the development of anti-platelet, anti-thrombotic drugs 28, 30 . Abciximab, the antigen-binding fragment (Fab) of a chimeric mouse-human monoclonal antibody against αIIbβ3 integrin, was the first integrin antagonist in clinical medicine 36 . Two additional parenteral, non-antibody αIIbβ3 integrin antagonists, eptifibatide 37 and tirofiban 38 , quickly followed for similar indications, and all three drugs work by directly blocking ligand binding to αIIbβ3 integrin. As knowledge pertaining to mechanisms of αIIbβ3 integrin signalling has increased in recent years, therapeutic blockade of specific intracellular facets of inside-out and/or outside-in αIIbβ3 integrin signalling remains an appealing, if only theoretical, possibility 39 . αVβ3 integrin. In comparison to αIIbβ3 integrin, αVβ3 integrin is more widely expressed, particularly in proliferative endothelial cells, where it has been implicated in aspects of angiogenesis, and integrin-dependent endothelial cell spreading in vitro 46, 47 . The role, if any, of αVβ3 or αMβ2 integrin-binding by abciximab in its anti-thrombotic effects in humans is unclear. Abciximab is indicated for use with heparin and aspirin as an adjunct for the prevention of cardiac ischaemic complications, either in patients undergoing percutaneous coronary intervention (PCI) or in patients with unstable angina who do not respond to conventional medical therapy and in whom PCI is planned within 24 hours (TABLE 1) .
Eptifibatide is a disulfide-linked, cyclic heptapeptide containing a 1-mercaptopropionyl residue, and it is based on the amino acid sequence Lys-Gly-Asp (KGD) in the snake venom barbourin 37, 44, 48 . Eptifibatide is highly selective for αIIbβ3 integrin and binds to the ligand-binding pocket of this integrin in a divalent-cation-sensitive manner, and it reversibly inhibits adhesive ligand binding and platelet aggregation. Eptifibatide is indicated for patients with non-ST segment elevation myocardial infarction (NSTEMI), including those who are to be managed medically and those undergoing PCI (TABLE 1) .
Tirofiban (N-(butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-l-tyrosine monohydrochloride monohydrate) is a highly selective small-molecule inhibitor of αIIbβ3 integrin that was approved for human use in 1999 (REFS 38, 44) . Similar to eptifibatide, tirofiban is highly selective for αIIbβ3 integrin and blocks ADP-induced platelet aggregation. Tirofiban is indicated to reduce the rate of thrombotic cardiovascular events in patients with NSTEMI who are undergoing PCI (TABLE 1) .
in vascular smooth muscle cells, monocytes, macrophages and some tumour cells 40 . αVβ3 integrin can interact with many of the same RGD-containing adhesive proteins as αIIbβ3 integrin can, but with a different affinity, and αVβ3 integrin can interact with a number of non-RGD-containing proteins in the extracellular matrix. Despite substantial efforts at drug development 10 , an αV integrin-directed antagonist, cilengitide, which blocks the binding of vitronectin to αVβ3 integrin, was not efficacious in clinical trials that aimed to limit tumour angiogenesis and progression in patients with glioblastoma 41 . Its failure in this context may be due to complexities in the mechanism of action of cilengitide, which depends on the dose and timing of administration, as was shown in mouse models 42 , as well as the difficulties inherent to treating a notoriously resistant neoplasm with a single targeted drug 43 . αIIbβ3 integrin in cardiovascular medicine Abciximab 36, 44 binds to αIIbβ3 integrin with nanomolar affinity and inhibits the binding of fibrinogen, von Willebrand factor and other RGD-containing adhesive ligands to human αIIbβ3 integrin. As a result, abciximab blocks agonist-induced aggregation of human platelets as well as downstream platelet responses that are dependent on aggregation 28, 44 . The epitope for this antibody is in the specificity-determining loop of the β3 integrin subunit, close to the metal ion-dependent adhesion site (MIDAS) 45 . In addition to αIIbβ3 integrin, abciximab has been reported to bind to αVβ3 integrin and, to a lesser extent, αMβ2 integrin, and it has also been reported to inhibit αVβ3 Adverse events with αIIbβ3 integrin antagonists. Unsurprisingly, the most serious adverse effects common to all parenteral αIIbβ3 integrin antagonists are bleeding and thrombocytopenia. The main underlying mechanism for thrombocytopenia is immunological but seems to vary depending on the drug 49 . In the case of abciximab, thrombocytopenia seems to be most frequently caused by the development of antibodies to murine sequences in the chimeric Fab. In individuals receiving eptifibatide or tirofiban, thrombocytopenia typically occurs during the drug infusion and seems to be most often caused by antibodies to extracellular epitopes in αIIbβ3 integrin that are exposed by binding of the drug. These antibodies may be pre-formed and naturally occurring in these individuals 49, 50 . If thrombocytopenia occurs in patients treated with any αIIbβ3 integrin antagonist, the drug must be discontinued and platelet transfusion must be given if clinically indicated.
Effect of newer anti-platelet and anti-thrombotic drugs. Currently, no active clinical trials testing new inhibitors of αIIbβ3 integrin are listed on the ClinicalTrials.gov website. This is largely owing to the introduction of inhibitors of P2Y purinoceptor 12 (P2Y 12 ) -such as cangrelor and the orally bioavailable the latter primarily owing to cardiovascular events 28, 30, 53 . The reasons for these failures are still debated, although three issues seem germane 54 . First, the successful studies with parenteral αIIbβ3 integrin antagonists used drug doses and infusion schemes that resulted in high-grade, continued occupancy of αIIbβ3 integrin (>80%) during the treatment phase. This degree and continuity of receptor inhibition might be very hard to maintain with an oral αIIbβ3 antagonist, such that periods of availability of αIIbβ3 integrin to fibrinogen and other adhesive ligands would be expected to occur, thus enabling aggregation of activated platelets at sites of vascular pathology. Second, most oral αIIbβ3 integrin antagonists are expected to change the conformation of the receptor upon binding, which could lead to an unintended partial agonist effect on platelets 55 . The failure of oral αIIbβ3 integrin inhibitors is a good example of how perfectly sound mechanistic reasoning (these drugs should have worked) paired with unfavourable pharmacokinetics and unexpected allosteric effects (conformation change) can result in adverse outcomes that were completely unpredictable until the clinical trial data became available.
Future prospects for αIIbβ3 integrin antagonists. Although αIIbβ3 integrin is a proven therapeutic target, the initial wave of clopidogrel, prasugrel and ticagrelor -and inhibitors of proteinase-activated receptor 1 (PAR1), all of which have decreased demand for antagonists of αIIbβ3 integrin. In ISAR-REACT-2, abciximab reduced the risk of adverse events in patients with NSTEMI who were undergoing PCI, even after optimal pretreatment with 600 mg of clopidogrel 51 . However, the use of αIIbβ3 integrin antagonists has decreased with the increased availability of newer, efficacious parenteral anticoagulants (such as bivalirudin) and newer P2Y 12 receptor antagonists that are more potent and/or act more rapidly than clopidogrel 52 . Nonetheless, the αIIbβ3 integrin antagonists appropriately remain in the cardiologist's arsenal, particularly for use in high-risk individuals undergoing PCI, including those in whom the use of P2Y 12 antagonists might have been delayed or is likely to be relatively ineffective.
Failure of oral αIIbβ3 antagonists.
Given the efficacy of parenteral αIIbβ3 integrin antagonists in the setting of acute coronary syndromes (which include NSTEMI, STEMI and unstable angina) and PCI, several oral agents selective for αIIbβ3 integrin were developed and tested in Phase III clinical trials. These studies showed that the use of these oral agents was associated with excess bleeding and mortality, failures of oral αIIbβ3 integrin antagonists effectively eliminated pharmaceutical companies from this development space. Recently, however, an αIIbβ3 integrinselective compound that does not induce a detectable conformational change in αIIbβ3 integrin when it binds to the RGD binding site was identified from a high-throughput drug screen 56 . Subsequent structure-based drug design and the development of a water-soluble congener resulted in a molecule, RUC-4, which has a sub-micromolar half-maximal inhibitory concentration (IC 50 ) for ADP-induced platelet aggregation, both in vitro and after intramuscular administration to non-human primates 56 . RUC-4 could be further evaluated for administration to patients with acute coronary syndromes in the pre-hospital setting, because the drug could be made available in a formulation for intramuscular administration, which is clearly advantageous over the intravenous administration of αIIbβ3 integrin antagonists in an ambulance setting.
Leukocyte integrins
Six integrins are expressed exclusively in leukocytes: αLβ2, αMβ2, αxβ2 (also known as CR4), αdβ2, α4β7 and αEβ7 integrins. Five of these integrins contain αI domains (FIG. 1) . αLβ2 has been shown by cryo-electron microscopy 57 and crystallography 58 to undergo very large conformational changes secondary to inside-out signalling, which are associated with an approximately 10,000-fold increase in ligand-binding affinity 11 .
Patients with LAD1 have hypomorphic or null mutations in the β2 chain (also known as CD18), which is common to the αLβ2, αMβ2, αxβ2 and αdβ2 integrins, and these patients have mild-to-severe inflammatory defects 59 . There are no known human genetic alterations in the four individual α-chains or in either of the β7 chains.
Leukocyte integrins have a prominent role in inflammation and immunity. Specifically, αLβ2 integrin is required for the formation of the immunological synapse 60 . Indeed, this integrin was initially named lymphocyte function-associated antigen 1 (LFA1) because of this association with lymphocyte function. Mice deficient in the gene that encodes the αL subunit have reduced lymphocyte numbers in their secondary lymphoid organs and a mild defect in inflammation 61 . αMβ2 integrin has a major role in host defence, especially against bacterial and fungal infections. αMβ2 integrin is also an important molecule in the recognition of complement C3bi-opsonized particles. Mice deficient in Itgam, which encodes the αM integrin subunit, determinant of gut-homing lymphocytes 67, 68 . αEβ7 integrin binds to E-cadherin and places intraepithelial lymphocytes near or inside the epithelial monolayer that lines the intestine. α4β1 integrin was originally identified on lymphocytes that were activated for extended periods and thus named very late antigen-4 (VLA4) 69 . α4β1 integrin binds to vascular cell adhesion molecule 1 (VCAM1) 70 and other ligands on endothelial cells and is involved in adhesion of effector, effector-memory and central-memory cells to many, if not all, inflamed organs.
The rationale for targeting leukocyte integrins is to modulate inflammation. An early and important observation in the field was that antibodies to α4β1 integrin can cure experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, have a defect in neutrophil apoptosis 62 and reduced proteinuria in a model of immune complex-induced kidney disease 63 . A single nucleotide polymorphism in human ITGAM is strongly associated with the development of lupus erythematosus 64, 65 . Mice deficient for αxβ2 integrin have no spontaneous phenotype, but this integrin was shown to have a role in a model of atherosclerosis 66 . Mice deficient in Itgb2, which encodes the β2 subunit that is common to four of the integrins with known roles in leukocytes, results in a very severe inflammatory disease with high neutrophil numbers, spontaneous infections and an inability of neutrophils to assemble the NADPH oxidase 6 . Both α4β7 and αEβ7 integrin direct lymphocyte trafficking to the intestinal tissues. α4β7 integrin is the major and defining The major findings of these trials were as follows:
• Reduced relapses by 68% versus placebo in two trials 102 • Combined treatment reduced relapse and disability progression more than IFNβ alone did 103 • Reduced visual loss 104 • Improved assessments of health-related quality of life 105, 106 • MRI evidence that the formation of new lesions was prevented 107 Additionally, some of these trials had major adverse effects:
• Progressive multifocal leukoencephalopathy (PML), a potentially fatal complication, with an estimated risk of 2 in 1,000 for patients treated for >2 years 108 • 6% of individuals receiving natalizumab developed efficacy-reducing antibodies Additionally, some of these trials had major adverse effects:
• A significant increase in circulating B and T lymphocytes at 1, 2 and 4 weeks • Because of the PML risk, natalizumab has effectively been displaced by drugs targeting β7-containing integrins *Crohn disease activity index, which ranges between 0 and 600 points 113 .
which spawned the clinical development of α4 subunit antagonists (see below and BOX 1).
Mice lacking all four β2-containing integrins or individual β2 integrins, or mice in which β2 integrins are blocked by antibodies, are protected in many models of ischaemia and reperfusion 71, 72 . α4β7 integrin is targeted by the antibody vedolizumab, which has recently proven useful for the treatment of inflammatory bowel diseases (IBDs), a group of diseases that includes Crohn disease and ulcerative colitis. α4β7 integrin is also targeted by another antibody, AMG181. α4β7 integrin does not contain an I-domain and binds predominantly to mucosal addressin cell adhesion molecule 1 (MAdCAM1), which is expressed on endothelial cells in tissues of the gastrointestinal tract 73 . MAdCAM1 is the target of a new antibody to treat IBD (see below).
αEβ7 integrin binds to E-cadherin and is thought to be involved in localizing leukocytes to gut epithelial cells. An antibody targeting the β7 subunit is in late-stage clinical development for IBDs (see below). infection, progressive multifocal leukoencephalopathy (PML, see BOX 2) . A topical αLβ2 integrin inhibitor, lifitegrast, recently successfully completed a Phase III clinical trial, the SONATA study, which examined the use of a lifitegrast-containing ophthalmic solution in patients with dry eye (see Medscape story in Further information). Lifitegrast is a small-molecule integrin antagonist designed to reduce inflammation by binding αLβ2 integrin and blocking the interaction with its cognate ligand, intercellular adhesion molecule 1 (ICAM1). ICAM1 is overexpressed in corneal and conjunctival tissues in patients with dry eye disease. In the SONATA study, adverse events occurred in 53.6% of patients in the lifitegrast-treated group and 32.4% of patients in the placebo-treated group, but there were no serious ocular adverse events or systemic toxicity, and discontinuation owing to adverse events was infrequent. The US Food and Drug Administration (FDA) granted lifitegrast priority review status on 9 April 2015.
The first widely successful drug targeting leukocyte integrins was natalizumab, which has indications in multiple sclerosis and A seventh leukocyte integrin, α4β1 integrin, is expressed on monocytes and lymphocytes, but, unlike the other six, it is also expressed on many other cells. α4β1 integrin binds to both a splice variant of fibronectin that contains the peptide sequence Ile-Leu-Asp-Val as well as to VCAM1 (REF. 70 ). These interactions support slow rolling, adhesion and transmigration, as well as pro-inflammatory signalling in the endothelial cells. α4β1 integrin has no I-domain and is targeted by the antibody natalizumab, which has indications in multiple sclerosis and Crohn disease (see below).
Targeting leukocyte integrins
Targeting leukocyte integrins has proven applications in diseases such as multiple sclerosis, Crohn disease and ulcerative colitis. Four leukocyte integrins, αLβ2, α4β1, α4β7 and αEβ7 integrins, have been targeted by monoclonal antibodies that have been investigated in patients. The αL integrin subunit is the target of efalizumab, which was previously on the market for psoriasis but was withdrawn in 2009 because of an association with a fatal brain • Clinical response at week 6 was significantly greater in the vedolizumab-treated group than in the placebo-treated group, remission rates were significantly higher in the vedolizumab-treated group and these patients had higher mucosal healing rates • Clinical remission (CDAI score of ≤150 points) and CDAI-100 response (≥100-point decrease in the CDAI score from baseline) at week 6 were significantly better in the vedolizumab-treated group than in the placebo-treated group, and this was maintained at week 52 • Remission rates and rates of CDAI-100 response at week 6 and week 10 were significantly higher in anti-TNF non-responders than in the placebo-treated group 120 • No evidence of PML (more than 2,700 patients treated and zero PML events reported, upper level of 95% confidence interval) • Low levels of anti-drug antibody formation 121 • No difference in safety data between drug and placebo CD, Crohn disease; CDAI, Crohn disease activity index (ranges between 0 and 600 points 113 ); IgG1, immunoglobulin G1; MAdCAM1, mucosal addressin cell adhesion molecule 1; PML, progressive multifocal leukoencephalopathy; TNF, tumour necrosis factor; UC, ulcerative colitis; UCCS, UC clinical score.
Crohn disease. All integrin-targeting drugs clinically approved for IBDs, which include Crohn disease and ulcerative colitis, are humanized monoclonal antibodies that target the α4 integrin subunit or the α4β7 integrin heterodimer (FIG. 3) . Antibodies that target the β7 integrin subunit and MAdCAM1 are currently in clinical trials.
Targeting α4-containing integrins in multiple sclerosis. The α4 subunit can pair with either the β1 or β7 subunits, so drugs that target α4 effectively inhibit two integrins: α4β1 and α4β7 (FIGS 1,3) . Natalizumab is a recombinant humanized immunoglobulin G4κ (IgG4κ) monoclonal antibody that binds to α4-containing integrins and blocks the binding of their physiological ligands. α4β1 integrin binds to VCAM1, which is expressed on inflamed endothelial cells, macrophages and other cells, and to alternatively spliced fibronectin, a component of the extracellular matrix. α4β7 binds to MAdCAM1, which is expressed on intestinal endothelial cells (FIG. 3) . These properties were demonstrated in vitro, as natalizumab effectively prevented adhesion of human Jurkat cells that expressed α4β1 integrin to purified recombinant VCAM1, and natalizumab also prevented the adhesion of RPMI-8866 cells that expressed α4β7 integrin to recombinant MAdCAM1. These data were complemented by in vivo studies of EAE in rodents. This model is mediated by T lymphocytes that infiltrate regions of the central nervous system via α4β1 integrin-VCAM1-mediated migration. A monoclonal antibody targeting α4 prevented leukocytes from crossing the blood-brain barrier, prevented the development of the neurological manifestations of EAE and reversed established disease 74 . In all, these results provided direct proof for the efficacy of natalizumab-like antibodies as anti-adhesion drugs in animal models. Natalizumab is effective in treating patients with multiple sclerosis (the clinical trials are summarized in BOX 1) . Notably, approximately 6% of individuals receiving natalizumab developed efficacy-reducing antibodies to the drug 75 . Natalizumab is approved in the United States and the European Union as a monotherapy for the treatment of patients with highly active relapsing and remitting multiple sclerosis who have not responded to prior treatments. The unexpected development of PML (BOX 2) in patients treated with natalizumab triggered a voluntary withdrawal of the drug from the market in February 2005. Remarkably, advocacy groups for patients in isolation. The drug was generated at Amgen by expression in CHO cells 79 and is administered via the subcutaneous route. Safety data were published in 2014 (REF. 80) and no cases of PML have been observed in patients treated with AMG 181. There are no published data regarding the similarities or differences in binding sites between AMG 181 and vedolizumab. One study (ClinicalTrials.gov identifier: NCT01290042), comparing four escalating doses of AMG 181 administered as multiple doses in healthy individuals and in individuals with active ulcerative colitis, has been completed but not yet published. A Phase I study (NCT01164904) in healthy volunteers and patients with ulcerative colitis was terminated; the reason for termination is not available. Two Phase II trials in patients with ulcerative colitis (NCT01694485) and Crohn disease (NCT01696396) are listed as active on ClinicalTrials.gov.
Etrolizumab. Etrolizumab is a humanized
IgG1 monoclonal antibody that is directed against the β7 integrin subunit, thus targeting both αEβ7 and α4β7 integrins (FIG. 3) , blocking their interactions with MAdCAM1 and E-cadherin, respectively. It is not known whether additional immunological functions would be affected by etrolizumab, but theoretically this antibody should target intestinal intraepithelial lymphocytes, which express αEβ7 integrin. A subset of dendritic cells that produce anti-inflammatory retinoic acid and support the development of regulatory T cells also express αEβ7 integrin 81 , and thus might also be targeted by etrolizumab. Preclinical studies showed that etrolizumab effectively inhibits migration of T cells to mucosal sites, without affecting their homing to non-mucosal tissue 82 . In a randomized, Phase I study (PRO145223) of the use of etrolizumab in patients with moderate-to-severe ulcerative colitis, the drug was safe and well tolerated 83 . Serious adverse effects included exacerbation of the disease and impaired wound healing in two patients who underwent colectomy. There was a decrease in the 'availability' of β7-containing receptors on target CD4 + lymphocytes, suggesting that etrolizumab administration might decrease the number of lymphocytes that home to the gut.
The results of a double-blind, placebocontrolled, randomized, Phase II study on the use of etrolizumab in patients with ulcerative colitis were recently reported 84 . Etrolizumab was safe and well tolerated, and no serious opportunistic infections were reported. In that study, etrolizumab was with multiple sclerosis lobbied the FDA to make natalizumab available again, because the benefits of this drug were so substantial. Natalizumab returned to the US market in July 2006 under a strict Tysabri outreach: unified commitment to health (TOUCH) monitoring programme. More than 100,000 patients with multiple sclerosis have been treated with natalizumab.
Targeting α4-containing integrins in IBD.
Natalizumab is also approved by the FDA as a remission-inductive and maintenancesustaining therapy for Crohn disease. The success of natalizumab in patients with this disease (see BOX 1 for clinical trials) provided a strong incentive to develop more specific drugs that target α4-containing integrins only in the intestinal tract. This was achieved by targeting α4β7 integrin, the β7 subunit or MAdCAM1.
Targeting α4β7 in IBD. Preclinical studies in cotton-top tamarins with spontaneous colitis provided evidence for an anti-inflammatory effect of α4β7 integrin blockade in experimental intestinal inflammation 76, 77 . Based on these results, vedolizumab (previously known as MLN-02, LDP-02, and MLN0002, and marketed as Entyvio; Millennium Pharmaceuticals), a humanized IgG1 monoclonal antibody, was developed. This antibody blocks binding of MAdCAM1 to α4β7 integrin by binding to the integrin heterodimer. The clinical trials of vedolizumab in Crohn disease and ulcerative colitis are summarized in TABLE 2; the drug is approved by the FDA for the treatment of these two diseases.
As the risk of PML is the limiting factor for the use of natalizumab, vedolizumab has effectively replaced natalizumab in clinical practice for the treatment of Crohn disease and ulcerative colitis. At the same time, these encouraging results have spawned studies into new indications and new drugs that affect β7 integrin. Potential new indications for vedolizumab include primary sclerosing cholangitis (as MAdCAM1 is expressed in the chronically inflamed livers of patients with this disease 78 ) and refractory pouchitis. No published clinical data are available at this time.
New integrin antagonists for IBD AMG 181. AMG 181 is a human monoclonal antibody (IgG2) against the α4β7 integrin heterodimer. AMG 181 is conceptually similar to vedolizumab, because it also binds to a combinatorial epitope, which means that it binds to neither the α4 nor β7 subunits more likely to lead to clinical remission at week 10 than was the placebo, however the higher dose did not provide added benefit. Interestingly, patients who did not previously respond to treatment with agents targeting tumour necrosis factor (TNF) fared worse than patients who were naive to anti-TNF treatment. Although the biological basis for this observation is currently unknown, the anti-TNF non-responder population could be enriched for individuals with the most therapy-resistant disease. The mechanisms of non-response are not clearly understood, but have tentatively been attributed to anti-drug antibodies or pharmacokinetics.
The study additionally found an increased number of CD4 + β7 + T cells in peripheral blood, which is consistent with the hypothesis that etrolizumab interferes with the recruitment of effector T cells to the intestine. However, the study investigators found no changes in the mRNA levels of β7, β1 or αE integrins in intestinal biopsies, which would have further supported this AJM 300. AJM 300 is an oral compound that acts as an antagonist of α4-containing integrins. This compound was developed by Ajinomoto Pharmaceuticals, and information regarding the molecular structure and binding site remains unpublished. Several studies have reported the efficacy of this small molecule in animal models of IBD. A manuscript was submitted and later withdrawn as the authors did not comply with journal requirements for publishing the molecular structure 86 . The results of a randomized, double-blind, placebocontrolled trial in Japanese patients with active Crohn disease was presented during the Digestive Diseases Week meeting in 2009 (REF. 87 ). AJM 300 was safe and well tolerated and showed a statistically significant improvement in clinical response rate in patients with moderately active ulcerative colitis. However, this drug is likely to cause PML at a rate similar to that of natalizumab, which would be an unacceptable risk for patients with ulcerative colitis. Further evaluation of the potential safety of AJM 300 in IBD will be required.
Targeting integrin ligands
Because targeting α4β7 integrin had been so successful, MAdCAM1 became an obvious target. MAdCAM1 is normally expressed in the mesentric lymph node and Peyer patches, but it becomes more widely expressed in other venules of the intestinal wall during inflammation. Many of the endothelial ligands for integrins share structural and genetic features with immunoglobulin molecules: they contain at least one immunoglobulin domain, comprising two β-pleated sheets held together by a disulfide bond. Among the many members of the immunoglobulin superfamily, several have established pathogenetic roles in IBD. ICAM1, VCAM1 and MAdCAM1 are all known to be involved in IBD, but only MAdCAM1 has gut-specific expression.
MAdCAM1: the endothelial α4β7 integrin ligand. MAdCAM1 levels are increased in the colon of animal models of colitis 88 , and in humans with IBD the number of intestinal mucosal vessels that stain positive for MAdCAM1 is increased 89 . TNF and interleukin 1 (IL-1) are abundant in areas of active inflammation in Crohn disease or ulcerative colitis, and these cytokines upregulate MAdCAM1 expression in the intestine, colon and mesenteric lymph nodes 88, 90 . MAdCAM1 is detected at extraintestinal sites, such as the joints, eyes, skin and liver 91 . Because these organs possibility. Interestingly, most patients with clinical remission at day 1 of treatment had high levels of αE integrin-expressing T cells in peripheral blood. This is an interesting observation, as the αEβ7 integrin heterodimer has been commonly associated with tolerogenic or immunoregulatory cells in populations of both T cells and dendritic cells. One possible explanation is that different doses of this drug result in distinct drug concentrations in tissues, and that at one concentration the drug interferes with the α4β7 integrin heterodimer but at another concentration it affects the αEβ7 integrin heterodimer. This could have consequences that would not be expected on the basis of the clinical experience with vedolizumab, which does not bind to the αEβ7 heterodimer. αEβ7 has been recently implicated in tissue resident memory cells 85 , however, both the functional role of αEβ7 in these cells and the role of these cells in chronic inflammatory processes are poorly understood.
Box 2 | Progressive multifocal leukoencephalopathy: a major complication
The widespread use of anti-integrin monoclonal antibodies for the treatment of inflammatory bowel disease, multiple sclerosis or psoriasis has been hampered by the occurrence of a rare but potentially fatal complication, progressive multifocal leukoencephalopathy (PML) 108 . This condition is the result of reactivation of a polyoma virus, John Cunningham virus (JCV). The risk for developing PML after treatment with natalizumab has been estimated to be approximately 2 in 1,000 for patients treated for more than 2 years. Until 2009, four cases were described within a cohort of 6,000 patients who had received efalizumab for the treatment of psoriasis. The unexpected development of PML in patients treated with natalizumab triggered its voluntary withdrawal from the market in February 2005 (it returned in July 2006 under Tysabri outreach: unified commitment to health (TOUCH) monitoring) and the withdrawl of efalizumab in 2009. PML seems to be a true drug effect, as none of multiple sclerosis, Crohn disease or psoriasis has been associated with the development of PML. There is no known treatment, prevention or cure for this condition and the infection usually leads to death or severe disability.
The pathogenesis of PML in patients receiving natalizumab is largely unknown. Nevertheless, it may be primarily associated with the natalizumab-induced blockade of the interaction between α4β1 integrin and vascular cell adhesion molecule 1 (VCAM1). Preventing this interaction may block the migration of JCV-specific lymphocytes to the central nervous system, including cytolytic T lymphocytes, which have been associated with increased survival in patients with PML 114 . Alternative pathogenic mechanisms, such as mobilization of JCV-infected pre-B cells from the bone marrow owing to an α4β1 integrin blockade, may also participate 115 . If blocking the α4β1 integrin-VCAM1 interaction is the mechanism that is mainly responsible for PML development in the central nervous system, then selective blockade of α4β7 integrin may not be associated with this complication. Indeed, there have been no cases of PML to date in patients treated with the specific anti-α4β7 integrin antibody, vedolizumab.
It is not clear whether PML is a class adverse effect. Cases of PML have also been reported in patients receiving rituximab 116 , an anti-CD20 monoclonal antibody that primarily targets B cells. Nevertheless, a causal association between this drug and PML cannot be directly established, as some of the conditions for which rituximab was administered (such as lymphoproliferative disorders, systemic lupus erythematosus and rheumatoid arthritis) may inherently increase the risk of developing PML. The frequency of PML in patients who are negative for JCV (around 50% of patients) is near zero, thus it is possible that anti-integrin antibodies might be safely used in subsets of JCV-seronegative patients.
The association between anti-integrin monoclonal antibodies and PML has been a substantial impediment to their widespread use in the treatment of inflammatory bowel disease. Current strategies to overcome this problem have focused on the careful pre-testing for JCV-specific antibodies in treatment candidates and thorough monitoring of JCV serologic conversion in actively treated patients. The primary end point, clinical remission, was significantly greater in the groups receiving the three lowest doses (7.5 mg, 22.5 mg and 75 mg) than in the group that received placebo. The secondary end point, mucosal healing, was significantly greater in the groups that received 22.5 mg and 75 mg of drug than in the group that received placebo, whereas the response (a decrease in Mayo score of ≥ 3 and ≥ 30% decrease from baseline) was greatest in the groups receiving 22.5 mg and 225 mg. This study was not powered to compare the different doses of drug, and so it is unclear whether the observed lower rate of clinical remission in the group that received 225 mg has a biological basis. There was no evidence of increased infections in mucosal tissues (gastrointestinal, nasal, splenic, bladder, uterine and lung) and no cases of PML were observed. Of note, a consistent finding for all end points was that the second lowest of the four doses tested was the most effective.
Another anti-MAdCAM1 antibody, PF-00547659, has been investigated for the treatment of Crohn disease. The results of a randomized, multicentre, double-blind, placebo-controlled study were presented at the Digestive Disease Week meeting in 2015 (REF. 95 ) Although the primary end pointdisease score -was not significantly different between any of the PF-00547659 doses and placebo, remission at week 12 seemed to be substantially higher in those patients with a median baseline C-reactive protein (CRP) level >18. The primary end point was not met owing to a high placebo response. However, PF-00547659 was pharmacologically active, as shown by a dose-related increase in circulating β7 + T lymphocytes and a sustained dose-related decrease in soluble MAdCAM1 in the blood; MAdCAM1 levels remained low during the study in patients with angiogenic endothelium in some, but not all, cancers. Theoretically, targeting β2-containing integrins could limit the infiltration of myeloid-derived suppressor cells, which are known to enhance tumour growth and metastasis. However, Itgb2-null mice and people with genetic deficiencies in ITGB2 have immunological phenotypes (such as LAD1), which suggests that severe host defence and inflammatory issues would arise if this integrin subunit were to be targeted.
The fact that only molecules targeting the ligand-binding site or the ligand itself have been successful in the clinic suggests that we do not know enough about the integrin conformational changes that occur during activation to successfully construct allosteric inhibitors. Theoretically, it might be possible to target talin 1, an adaptor molecule that regulates the affinity of β2-and β3-containing integrins. However, knockout of Tln1 (which encodes talin 1) in mice is lethal 98 , suggesting that talin 1 has other important functions. Kindlin 3 is another adaptor molecule involved in integrin-mediated leukocyte and platelet adhesion. Kindlin 3 deficiency in mice 99 and people 34 results in severe bleeding and an infectious diathesis. After integrins bind to their ligands, outside-in signalling ensues 4, 100 , and there are known drug targets in this signalling pathway, such as tyrosine protein kinase SYK 101 and SRC kinases 100 . Targeting these tyrosine kinases cannot be expected to be specific for integrin signalling, because they are also involved in signalling from the antibody crystallisable fragment (Fc) receptor and the B cell receptor. who received PF-00547659. Circulating CD4 + central memory T lymphocytes expressing β7-containing integrins increased at weeks 8 and 12 in patients treated with PF-00547659 in a dose-dependent manner. This suggests that MAdCAM1 is relevant to the rolling and adhesion of α4β7 integrincontaining lymphocytes in these patients, and that blocking MAdCAM1 releases these lymphocytes into the circulation. Interestingly, higher rates of remission in patients with high levels of CRP were also observed in the natalizumab trials, which were completed nearly a decade ago. Objective outcomes other than disease score will be needed for future trials in Crohn disease. Towards this end, endoscopic, histological and magnetic resonance imaging outcomes are being extensively discussed.
Other ligands that could be targeted include ICAM1, which is a ligand for αLβ2 and αMβ2 integrins, and VCAM1, which is a ligand for α4β1 integrin. ICAM1 was targeted by monoclonal antibody mAb RR6.5 (Enlimomab, Boehringer Ingelheim) early on 96 , but this agent was not effective in a clinical trial of 625 patients with ischaemic stroke who were treated within 6 hours of the onset of stroke 97 . VCAM1 is expressed broadly on endothelial cells but is also expressed by macrophages. Notably, because VCAM1 is the main ligand of α4β1 integrin, blocking VCAM1 would be expected to potentially cause PML.
The experience with integrin-targeted drugs in cancer is limited to those directed against αVβ3 integrin, which is associated 
Conclusions
The development and demonstrated efficacy of integrin antagonists are prime examples of translational medicine whereby a deep fundamental knowledge of integrin biology has informed the design of antibody, peptide and small-molecule drugs that were successful in Phase III clinical trials. In turn, the results and adverse events observed in these trials have informed our understanding of pathophysiology. Integrin-targeting drugs have found four main indications: thrombosis prevention after PCI (for αIIbβ3 integrin), ulcerative colitis and Crohn disease (for α4β7 integrin) and multiple sclerosis (for α4β7 and α4β1 integrins). All approved drugs prevent the target integrin from binding to ligands. With the exception of natalizumab, which carries a substantial risk for PML, integrin-targeting drugs have proven to be remarkably safe and effective. Hundreds of thousands of patients have benefited from these drugs. In the future, the indications for existing integrin antagonists, particularly those that target α4-or β7-containing integrins, are likely to expand. Antibody drugs targeting integrin ligands are emerging, as exemplified by the antibodies to MAdCAM1, and could contribute to the management of integrin-associated diseases in the future.
